Data gathered: April 24
AI Stock Analysis - Editas Medicine (EDIT)
Analysis generated April 24, 2025. Powered by Chat GPT.
Editas Medicine is a biotech company focused on using CRISPR technology to develop ground-breaking treatments for genetic disorders. The company aims to transform the healthcare landscape by providing precision gene-editing solutions. Leveraging its core CRISPR Cas9 and Cas12a gene editing technologies, Editas Medicine is actively engaging in clinical trials and R&D activities to optimize therapeutic outcomes. Despite promising technologies, the company faces significant challenges, including regulatory approval hurdles and competition from other entities in the biotech space.
Stock Alerts - Editas Medicine (EDIT)
 |
Editas Medicine | April 23 Price is up by 7.1% in the last 24h. |
|
Editas Medicine | April 22 Price is up by 7.5% in the last 24h. |
|
Editas Medicine | April 21 Price is up by 7.8% in the last 24h. |
|
Editas Medicine | April 16 Price is down by -7% in the last 24h. |
Alternative Data for Editas Medicine
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 17,000 | Sign up | Sign up | Sign up |
| Employee Rating | 72 | Sign up | Sign up | Sign up |
| Google Trends | 11 | Sign up | Sign up | Sign up |
| Patents | 87 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 11 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 17,184 | Sign up | Sign up | Sign up |
| Twitter Mentions | 19 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | 40 | Sign up | Sign up | Sign up |
| Business Outlook | 60 | Sign up | Sign up | Sign up |
| Linkedin Employees | 287 | Sign up | Sign up | Sign up |
About Editas Medicine
Editas Medicine is a clinical-stage biotechnology company which is developing therapies based on CRISPR–Cas9 gene editing technology. Editas is based in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
| Price | $1.61 |
| Target Price | Sign up |
| Volume | 1,110,000 |
| Market Cap | $131M |
| Year Range | $0.98 - $4.1 |
| Dividend Yield | 0% |
| Analyst Rating | 24% buy |
| Industry | Biotechnology |
In the news
 |
Editas Medicine, Inc. (NASDAQ:EDIT) institutional owners may be pleased with recent gains after 71% loss over the past yearApril 22 - Yahoo |
 |
Leerink Partnrs Predicts Editas Medicine Q3 EarningsApril 19 - ETF Daily News |
|
Analysts Offer Predictions for Editas Medicine Q1 EarningsApril 17 - ETF Daily News |
|
Sei Investments Co. Takes $106,000 Position in Editas Medicine, Inc. (NASDAQ:EDIT)April 12 - ETF Daily News |
Editas Medicine : Corporate Effectiveness Report April 2025 (3731af)April 11 - Finnhub |
|
|
Raymond James Financial Inc. Takes Position in Editas Medicine, Inc. (NASDAQ:EDIT)April 10 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q4 '24 | 31M | 29M | 2M | -45M | 0 | -0.550 |
| Q3 '24 | 61,000 | 18M | -18M | -62M | -61M | -0.750 |
| Q2 '24 | 510,000 | 18M | -18M | -68M | -70M | -0.820 |
| Q1 '24 | 1.1M | 19M | -18M | -62M | -66M | -0.760 |
| Q4 '23 | 62M | 14M | 47M | -19M | -22M | -0.230 |
Insider Transactions View All
| Burkly Linda filed to sell 70,245 shares at $1.7. March 5 '25 |
| Lucera Erick filed to sell 112,720 shares at $1.7. March 5 '25 |
| O'Neill Gilmore Neil filed to sell 295,474 shares at $1.7. March 5 '25 |
| Mei Baisong filed to sell 133,354 shares at $2.1. December 5 '24 |
| O'Neill Gilmore Neil filed to sell 312,106 shares at $2.1. December 5 '24 |
Similar companies
Read more about Editas Medicine (EDIT) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Editas Medicine?
The Market Cap of Editas Medicine is $131M.
What is the current stock price of Editas Medicine?
Currently, the price of one share of Editas Medicine stock is $1.61.
How can I analyze the EDIT stock price chart for investment decisions?
The EDIT stock price chart above provides a comprehensive visual representation of Editas Medicine's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Editas Medicine shares. Our platform offers an up-to-date EDIT stock price chart, along with technical data analysis and alternative data insights.
Does EDIT offer dividends to its shareholders?
As of our latest update, Editas Medicine (EDIT) does not offer dividends to its shareholders. Investors interested in Editas Medicine should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Editas Medicine?
Some of the similar stocks of Editas Medicine are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.